Projects per year
Personal profile
Research interests
The long-term research interest in Dr. Shengyu Yang’s lab is to understand the mechanisms underlying cancer metastasis and developing novel therapeutic strategies in the prevention and treatment of cancer metastasis.
The research in the lab currently focus on two areas related to mitochondrial signaling and metabolism in cancer metastasis.
The first area of research effort is to understand how the actin cytoskeleton remodeling in lung adenocarcinoma promotes metastatic colonization by controlling mitochondrial DNA homeostasis and augmenting mitochondrial oxidative phosphorylation. The second area of research effort is to understand the role of mitochondrial calcium signaling in the control of metabolic stress resistance by activating the Keap1-Nrf2 antioxidant response program in metastatic pancreatic cancer.
Teaching and educational interests
Dr. Shengyu Yang is co-directing a new course for medical students at Penn State College of Medicine, Mitochondria in Physiology and Diseases, with Dr. Katherine Aird.
Dr. Yang also lectures on receptor tyrosine kinase signaling, cancer metastasis and mitochondrial dynamics to graduate students.
Education/Academic qualification
Postdoctoral Fellowship, Weill Cornell Medical College
… → 2010
Biophysics, PhD, Chinese Academy of Science
… → 2001
BS, Xiamen University
… → 1996
Fingerprint
Dive into the research topics where Shengyu Yang is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 6 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects
-
A novel role of fascin in cancer metastasis
Yang, S. & YANG, S.
12/4/18 → 11/30/21
Project: Research project
-
Store-Operated Calcium Entry in Tumor Invasion and Metastasis
Yang, S., YANG, S. & YANG, S.
12/3/13 → 11/30/19
Project: Research project
Research output
-
How does fascin promote cancer metastasis?
Lin, S., Taylor, M. D., Singh, P. K. & Yang, S., Mar 2021, In: FEBS Journal. 288, 5, p. 1434-1446 13 p.Research output: Contribution to journal › Review article › peer-review
Open Access3 Scopus citations -
Serum insulin-like growth factor binding protein 2 levels as biomarker for pancreatic ductal adenocarcinoma-associated malnutrition and muscle wasting
Dong, J., Yu, J., Li, Z., Gao, S., Wang, H., Yang, S., Wu, L., Lan, C., Zhao, T., Gao, C., Liu, Z., Wang, X. & Hao, J., 2021, (Accepted/In press) In: Journal of Cachexia, Sarcopenia and Muscle.Research output: Contribution to journal › Article › peer-review
Open Access -
ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4
Zhou, T., Liu, J., Xie, Y., Yuan, S., Guo, Y., Bai, W., Zhao, K., Jiang, W., Wang, H., Wang, H., Zhao, T., Huang, C., Gao, S., Wang, X., Yang, S. & Hao, J., 2020, (Accepted/In press) In: Gut.Research output: Contribution to journal › Article › peer-review
-
IL-37/ STAT3/ HIF-1α negative feedback signaling drives gemcitabine resistance in pancreatic cancer
Zhao, T., Jin, F., Xiao, D., Wang, H., Huang, C., Wang, X., Gao, S., Liu, J., Yang, S. & Hao, J., 2020, In: Theranostics. 10, 9, p. 4088-4100 13 p.Research output: Contribution to journal › Article › peer-review
Open Access7 Scopus citations -
PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC
Wang, X., Li, X., Wei, X., Jiang, H., Lan, C., Yang, S., Wang, H., Yang, Y., Tian, C., Xu, Z., Zhang, J., Hao, J. & Ren, H., Dec 1 2020, In: Signal Transduction and Targeted Therapy. 5, 1, 38.Research output: Contribution to journal › Article › peer-review
Open Access13 Scopus citations